NO20070162L - Krystallinske former av (-)-(1R,2R)-3-(3-dimetylamino- 1-etyl-2-metylpropyl)-fenol-hydroklorid - Google Patents

Krystallinske former av (-)-(1R,2R)-3-(3-dimetylamino- 1-etyl-2-metylpropyl)-fenol-hydroklorid

Info

Publication number
NO20070162L
NO20070162L NO20070162A NO20070162A NO20070162L NO 20070162 L NO20070162 L NO 20070162L NO 20070162 A NO20070162 A NO 20070162A NO 20070162 A NO20070162 A NO 20070162A NO 20070162 L NO20070162 L NO 20070162L
Authority
NO
Norway
Prior art keywords
methylpropyl
dimethylamino
ethyl
phenol hydrochloride
crystalline forms
Prior art date
Application number
NO20070162A
Other languages
English (en)
Other versions
NO338605B1 (no
Inventor
Andreas Fischer
Helmut Buschmann
Michael Gruss
Dagmar Lischke
Original Assignee
Gruenenthal Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34925507&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20070162(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gruenenthal Gmbh filed Critical Gruenenthal Gmbh
Publication of NO20070162L publication Critical patent/NO20070162L/no
Publication of NO338605B1 publication Critical patent/NO338605B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
    • C07C217/62—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C213/10—Separation; Purification; Stabilisation; Use of additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/48—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups
    • C07C215/54—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Det er beskrevet en ny krystallinsk form av (-)-(1R,2R)-3-(3-dimetylamino-l-etyl-2metylpropyl)-fenol hydroklorid, fremgangsmåte for fremstilling av denne, fremgangsmåter for anvendelse og farmasøytiske preparater inneholdende denne.
NO20070162A 2004-06-28 2007-01-09 Krystallinske former av (-)-(1R,2R)-3-(3-dimetylamino-1-etyl-2-metylpropyl)-fenol hydroklorid, fremgangsmåte for fremstilling samt anvendelse derav NO338605B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04015091A EP1612203B1 (en) 2004-06-28 2004-06-28 Crystalline forms of (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride
PCT/EP2005/006884 WO2006000441A2 (en) 2004-06-28 2005-06-27 Crystalline forms of (-)-(1r,2r)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride

Publications (2)

Publication Number Publication Date
NO20070162L true NO20070162L (no) 2007-01-24
NO338605B1 NO338605B1 (no) 2016-09-12

Family

ID=34925507

Family Applications (3)

Application Number Title Priority Date Filing Date
NO20070162A NO338605B1 (no) 2004-06-28 2007-01-09 Krystallinske former av (-)-(1R,2R)-3-(3-dimetylamino-1-etyl-2-metylpropyl)-fenol hydroklorid, fremgangsmåte for fremstilling samt anvendelse derav
NO20160914A NO341239B1 (no) 2004-06-28 2016-05-30 Krystallinsk form A av (-)-(1R,2R)-3-(3-dimetylamino-1-etyl-2-metylpropyl)-fenol hydroklorid for anvendelse som aktiv ingrediens i farmasøytiske preparater og farmasøytisk preparat inneholdende denne for anvendelse i behandling av smerte eller urin inkontinens
NO20171103A NO343922B1 (no) 2004-06-28 2017-07-04 Farmasøytisk preparat for oral administrering inneholdende som aktiv ingrediens krystallinsk form A av (-)-(1R,2R)-3-(3-dimetylamino-1-etyl-2-metylpropyl)-fenol hydroklorid og anvendelse derav for fremstilling av et medikament for behandling av smerte eller urin inkontinens

Family Applications After (2)

Application Number Title Priority Date Filing Date
NO20160914A NO341239B1 (no) 2004-06-28 2016-05-30 Krystallinsk form A av (-)-(1R,2R)-3-(3-dimetylamino-1-etyl-2-metylpropyl)-fenol hydroklorid for anvendelse som aktiv ingrediens i farmasøytiske preparater og farmasøytisk preparat inneholdende denne for anvendelse i behandling av smerte eller urin inkontinens
NO20171103A NO343922B1 (no) 2004-06-28 2017-07-04 Farmasøytisk preparat for oral administrering inneholdende som aktiv ingrediens krystallinsk form A av (-)-(1R,2R)-3-(3-dimetylamino-1-etyl-2-metylpropyl)-fenol hydroklorid og anvendelse derav for fremstilling av et medikament for behandling av smerte eller urin inkontinens

Country Status (27)

Country Link
US (16) US20070213405A1 (no)
EP (2) EP1612203B1 (no)
JP (1) JP4990764B2 (no)
KR (1) KR101096501B1 (no)
CN (1) CN1997621B (no)
AR (2) AR049949A1 (no)
AT (2) ATE368639T1 (no)
AU (1) AU2005256512B2 (no)
BR (2) BRPI0512792A (no)
CA (1) CA2572147C (no)
CY (2) CY1106929T1 (no)
DE (2) DE602004007905T2 (no)
DK (2) DK1612203T3 (no)
EC (1) ECSP17046065A (no)
ES (2) ES2291780T3 (no)
HR (1) HRP20110050T8 (no)
IL (1) IL180373A (no)
MX (1) MXPA06014741A (no)
NO (3) NO338605B1 (no)
NZ (1) NZ551605A (no)
PE (1) PE20060372A1 (no)
PL (2) PL1612203T3 (no)
PT (2) PT1612203E (no)
RU (1) RU2423345C2 (no)
SI (2) SI1612203T1 (no)
WO (1) WO2006000441A2 (no)
ZA (1) ZA200700774B (no)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
PT1612203E (pt) * 2004-06-28 2007-08-20 Gruenenthal Gmbh ''formas cristalinas de cloridrato de (-) - (1r,2r) - 3 -(3-dimetilamino-l-etil - 2 - metilpropil) fenol''
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE102007011485A1 (de) 2007-03-07 2008-09-11 Grünenthal GmbH Darreichungsform mit erschwertem Missbrauch
DE102007019417A1 (de) * 2007-04-23 2008-11-13 Grünenthal GmbH Tapentadol zur Schmerzbehandlung bei Arthrose
CN104447360B (zh) * 2007-12-07 2017-04-12 格吕伦塔尔有限公司 (1r,2r)‑3‑(3‑二甲基氨基‑1‑乙基‑2‑甲基‑丙基)‑苯酚的结晶变体
CA2713128C (en) 2008-01-25 2016-04-05 Gruenenthal Gmbh Pharmaceutical dosage form
AU2009243681B2 (en) 2008-05-09 2013-12-19 Grunenthal Gmbh Process for the preparation of an intermediate powder formulation and a final solid dosage form under usage of a spray congealing step
US20100272815A1 (en) * 2009-04-28 2010-10-28 Actavis Group Ptc Ehf Amorphous form of tapentadol hydrochloride
KR101738369B1 (ko) 2009-07-22 2017-05-22 그뤼넨탈 게엠베하 핫 멜트 압출된 제어 방출 투여형
CN102639118B (zh) 2009-07-22 2015-07-29 格吕伦塔尔有限公司 氧化稳定的抗干扰剂型
US8288592B2 (en) 2009-09-22 2012-10-16 Actavis Group Ptc Ehf Solid state forms of tapentadol salts
EP2566461A2 (de) 2010-05-05 2013-03-13 Ratiopharm GmbH Festes tapentadol in nicht-kristalliner form
CN110015955A (zh) 2010-07-23 2019-07-16 格吕伦塔尔有限公司 3-(3-二甲基氨基-1-乙基-2-甲基-丙基)-苯酚的盐或共晶体
BR112013005194A2 (pt) 2010-09-02 2016-05-03 Gruenenthal Gmbh forma de dosagem resistente à violação compreendendo sal inorgânico
TWI516286B (zh) 2010-09-02 2016-01-11 歌林達股份有限公司 含陰離子聚合物之抗破碎劑型
WO2012051246A1 (en) 2010-10-12 2012-04-19 Ratiopharm Gmbh Tapentadol hydrobromide and crystalline forms thereof
CN103501775A (zh) * 2011-03-04 2014-01-08 格吕伦塔尔有限公司 他喷他多的胃肠外给药
MX388963B (es) 2011-03-04 2025-03-20 Gruenenthal Gmbh Formulacion farmaceutica acuosa de tapentadol para administracion oral
ES2910085T3 (es) 2011-03-04 2022-05-11 Gruenenthal Gmbh Composición farmacéutica acuosa semisólida que contiene tapentadol
BR112014001091A2 (pt) 2011-07-29 2017-02-14 Gruenenthal Gmbh comprimido resistente à adulteração que fornece liberação imediata do fármaco
EA201400172A1 (ru) 2011-07-29 2014-06-30 Грюненталь Гмбх Устойчивая к разрушению таблетка, которая обеспечивает немедленное высвобождение лекарственного средства
WO2013111161A2 (en) * 2012-01-10 2013-08-01 Msn Laboratories Limited Process for the preparation of 3-aryl-2-methyl-propanamine derivatives and polymorphs thereof
WO2013120466A1 (en) 2012-02-17 2013-08-22 Zentiva, K.S. A new solid form of tapentadol and a method of its preparation
MX356421B (es) 2012-02-28 2018-05-29 Gruenenthal Gmbh Forma de dosificacion resistente a la manipulacion indebida que comprende un compuesto farmacologicamente activo y un polimero anionico.
EP2838512B1 (en) 2012-04-18 2018-08-22 Grünenthal GmbH Tamper resistant and dose-dumping resistant pharmaceutical dosage form
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
CZ304576B6 (cs) * 2012-07-24 2014-07-16 Zentiva, K.S. Oxalát TAPENTADOLU a způsob jeho přípravy
CN102924303B (zh) * 2012-10-31 2013-11-20 合肥市新星医药化工有限公司 盐酸他喷他多晶型c及其制备方法和应用
US9737490B2 (en) 2013-05-29 2017-08-22 Grünenthal GmbH Tamper resistant dosage form with bimodal release profile
EP3003279A1 (en) 2013-05-29 2016-04-13 Grünenthal GmbH Tamper-resistant dosage form containing one or more particles
EP2808319A1 (en) 2013-05-31 2014-12-03 Arevipharma GmbH 3-[3-(Dimethylamino)-1-ethyl-2-methylpropyl]phenol resin complex
BR112016000194A8 (pt) 2013-07-12 2019-12-31 Gruenenthal Gmbh forma de dosagem resistente à violação contendo o polímero de acetato de etileno-vinila
EP2845625A1 (en) * 2013-09-04 2015-03-11 Grünenthal GmbH Tapentadol for use in the treatment of fibromyalgia and chronic fatigue syndrome
USD730877S1 (en) 2013-09-06 2015-06-02 Plantronics, Inc. Communications headset
US9599565B1 (en) * 2013-10-02 2017-03-21 Ondax, Inc. Identification and analysis of materials and molecular structures
WO2015071248A1 (en) 2013-11-15 2015-05-21 Synthon B.V. Abuse-proofed extended release pharmaceutical composition comprising tapentadol
EP3073994A1 (en) 2013-11-26 2016-10-05 Grünenthal GmbH Preparation of a powdery pharmaceutical composition by means of cryo-milling
CZ307492B6 (cs) 2014-02-04 2018-10-17 Zentiva, K.S. Pevná forma maleátu tapentadolu a způsob její přípravy
GB2523089A (en) * 2014-02-12 2015-08-19 Azad Pharmaceutical Ingredients Ag Stable polymorph form B of tapentadol hydrochloride
WO2015173195A1 (en) 2014-05-12 2015-11-19 Grünenthal GmbH Tamper resistant immediate release capsule formulation comprising tapentadol
EA201692388A1 (ru) 2014-05-26 2017-05-31 Грюненталь Гмбх Лекарственная форма в виде множества частиц, защищенная от вызываемого этанолом сброса дозы
PE20171651A1 (es) 2015-03-27 2017-11-13 Gruenenthal Chemie Formulacion estable para administracion parenteral de tapentadol
WO2016170097A1 (en) 2015-04-24 2016-10-27 Grünenthal GmbH Tamper-resistant dosage form with immediate release and resistance against solvent extraction
JP2018526414A (ja) 2015-09-10 2018-09-13 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 乱用抑止性の即放性製剤を用いた経口過剰摂取に対する保護
PL3445742T3 (pl) 2016-04-19 2020-05-18 Ratiopharm Gmbh Krystaliczny fosforan tapentadolu
EP3515412B1 (en) 2016-09-23 2025-04-23 Grünenthal GmbH Stable formulation for parenteral administration of tapentadol
EP3585370A1 (en) 2017-02-23 2020-01-01 Grünenthal GmbH Tapentadol as local anesthetic
CA3196954A1 (en) 2020-11-03 2022-05-12 Josep Bassaganya-Riera Crystalline forms of piperazine-1,4-diylbis((6-(1h-benzoi[d]imidazo-2-yl)pyridin-2yl)methanone) as lancl2 modulators

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4426245A1 (de) 1994-07-23 1996-02-22 Gruenenthal Gmbh 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung
CZ297679B6 (cs) * 1996-08-14 2007-03-07 G. D. Searle & Co. Krystalická forma B 4-[5-methyl-3-fenylizoxazol-4-yl]benzensulfonamidu
AU2002212340B2 (en) * 2000-10-31 2006-12-14 Sandoz Ag Crystalline forms of venlafaxine hydrochloride
US20050176790A1 (en) * 2001-02-28 2005-08-11 Johannes Bartholomaus Pharmaceutical salts
UA77000C2 (en) * 2001-09-13 2006-10-16 Kissei Pharmaceutical Crystalline form of hydroxynorephedrine derivative
PE20030527A1 (es) * 2001-10-24 2003-07-26 Gruenenthal Chemie Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil) fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen
PT1612203E (pt) * 2004-06-28 2007-08-20 Gruenenthal Gmbh ''formas cristalinas de cloridrato de (-) - (1r,2r) - 3 -(3-dimetilamino-l-etil - 2 - metilpropil) fenol''
CN104447360B (zh) * 2007-12-07 2017-04-12 格吕伦塔尔有限公司 (1r,2r)‑3‑(3‑二甲基氨基‑1‑乙基‑2‑甲基‑丙基)‑苯酚的结晶变体

Also Published As

Publication number Publication date
IL180373A0 (en) 2007-06-03
PL1799633T3 (pl) 2011-06-30
US20200102261A1 (en) 2020-04-02
NZ551605A (en) 2010-01-29
US20140296346A1 (en) 2014-10-02
NO20160914A1 (no) 2007-01-24
BR122018014454B8 (pt) 2021-07-27
BRPI0512792A (pt) 2008-04-08
HRP20110050T8 (en) 2011-03-31
CY1111530T1 (el) 2015-08-05
AU2005256512B2 (en) 2011-05-19
CN1997621A (zh) 2007-07-11
DE602004007905T2 (de) 2008-05-08
SI1799633T1 (sl) 2011-05-31
US20180029976A1 (en) 2018-02-01
US20100160447A1 (en) 2010-06-24
ES2359504T3 (es) 2011-05-24
DE602004007905D1 (de) 2007-09-13
US20170166515A1 (en) 2017-06-15
NO338605B1 (no) 2016-09-12
SI1612203T1 (sl) 2007-12-31
PL1612203T3 (pl) 2007-12-31
CA2572147C (en) 2012-10-30
PE20060372A1 (es) 2006-05-08
KR20070039929A (ko) 2007-04-13
ES2291780T3 (es) 2008-03-01
CY1106929T1 (el) 2012-09-26
US20210261492A1 (en) 2021-08-26
AU2005256512A1 (en) 2006-01-05
HRP20110050T1 (hr) 2011-02-28
US20110294898A1 (en) 2011-12-01
WO2006000441A2 (en) 2006-01-05
ATE496021T1 (de) 2011-02-15
US20200385334A1 (en) 2020-12-10
CN1997621B (zh) 2011-06-15
EP1612203A1 (en) 2006-01-04
WO2006000441A3 (en) 2006-05-04
EP1612203B1 (en) 2007-08-01
NO341239B1 (no) 2017-09-25
NO20171103A1 (no) 2007-01-24
JP2008504326A (ja) 2008-02-14
AR116052A2 (es) 2021-03-25
US7994364B2 (en) 2011-08-09
US20140011886A1 (en) 2014-01-09
US20160122287A1 (en) 2016-05-05
US20180230082A1 (en) 2018-08-16
JP4990764B2 (ja) 2012-08-01
US20070213405A1 (en) 2007-09-13
IL180373A (en) 2012-05-31
PT1612203E (pt) 2007-08-20
MXPA06014741A (es) 2007-02-12
DE602005026031D1 (de) 2011-03-03
EP1799633A2 (en) 2007-06-27
RU2007103297A (ru) 2008-08-10
AR049949A1 (es) 2006-09-20
EP1799633B1 (en) 2011-01-19
ATE368639T1 (de) 2007-08-15
CA2572147A1 (en) 2006-01-05
BR122018014454B1 (pt) 2019-09-03
PT1799633E (pt) 2011-03-07
US20230174458A1 (en) 2023-06-08
US20190062263A1 (en) 2019-02-28
ECSP17046065A (es) 2018-11-30
DK1799633T3 (da) 2011-03-28
ZA200700774B (en) 2008-09-25
RU2423345C2 (ru) 2011-07-10
KR101096501B1 (ko) 2011-12-20
US20090186947A1 (en) 2009-07-23
DK1612203T3 (da) 2007-12-03
NO343922B1 (no) 2019-07-08
US20120302643A1 (en) 2012-11-29

Similar Documents

Publication Publication Date Title
NO20070162L (no) Krystallinske former av (-)-(1R,2R)-3-(3-dimetylamino- 1-etyl-2-metylpropyl)-fenol-hydroklorid
NO20090376L (no) Fremgangsmate for fremstilling av (1R,2R)-3-(3-dimetylamino-1-etyl-2-metyl-propyl)-fenol
NO20080186L (no) Heterosykliske aspartylproteaseinhibitorer, fremstilling og anvendelse derav
NO20062884L (no) AKT-proteinkinaseinhibitorer
WO2006007448A3 (en) Pharmaceutical co-crystal compositions and related methods of use
MXPA05009367A (es) Antagonistas del receptor opioide.
HUP0303128A2 (hu) O-dezmetil-venlafaxin új szukcinátsója, eljárás az előállításukra, alkalmazása és ezt tartalmazó gyógyszerkészítmény
EA200501849A1 (ru) Производные пиразолохиназолина: способ получения и применение в качестве ингибиторов киназ
NO20100250L (no) Farmasoytisk preparat som innbefatter en S1P reseptoragonist og en sukkeralkohol, og framgangsmate til fremstilling derav
NO20073959L (no) Kinazolinderivat, fremgangsmate for fremstilling og anvendelse derav for inhibering av vekst av kreftceller
NO20053088L (no) Farmasoytisk preparat inneholdende en beta-3-adrenoseptoragonist og en serotonin og/eller norepinefrin-gjenopptakelsesinhibitor og anvendelse av nevnte preparat for behandling av blaeredysfunksjon.
DK1506185T3 (da) Forbindelser og deres anvendelse som 5-HT-inhibitorer
DK2054418T3 (da) Dihydrothieno-pyrimidiner som AKT-proteinkinase-inhibitorer
SE0401762D0 (sv) Novel compounds
TW200508195A (en) 3-aminopyrrolidines as inhibitors of monoamine uptake
NO20091334L (no) Fremgangsmate for syntese av klopidogrel og nye former for farmasoytisk akseptable salter derav
WO2004052858A3 (en) Inhibitors of monoamine uptake
SE0401655D0 (sv) New compounds
SE0403086D0 (sv) Compounds
DE60225694D1 (de) Fexofenadine hydrochlorid polymorph
NO20091771L (no) Ny krystall av (S)-(+)-2-(2-klorfenyl)-2-hydroksyetylkarbamat
DE602006019830D1 (de) Tetrahydro- und dihydrochinazolinone
MX2024005157A (es) 2-(aril-2-il)morfolina y derivado deuterado de esta, metodo de preparacion de estos y aplicacion de estos.
EA200300771A1 (ru) Новая соль бензоилгуанидина
NO20091231L (no) Polymorf av (R)-3-(2-hydroksy-2, 2-difenyl-acetoksy)-1-(isoksazol-S-ylcarbamoyl-metyl)-1-azoni A-bicyklo-[2,2,2]oktanbromid